Revelation Biosciences, Inc. (REVB) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is James Rolke.
REVB has IPO date of 2020-11-17, 8 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $4.46M.
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
